Prevention of heart failure: Effective strategies to combat the growing epidemic

Reviews in Cardiovascular Medicine

Volumn 4, Issue 1, 2003, Pages 8-17

  Fonarow, Gregg C ^a   Horwich, Tamara B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asymptomatic left ventricular dysfunction; Diabetes; Heart failure; Hypertension; Ischemic heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; PLACEBO; RAMIPRIL; SIMVASTATIN; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; EPIDEMIC; FAMILY HISTORY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORBIDITY; MORTALITY; OBESITY; PEPTIDE ANALYSIS; PREVALENCE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SYMPTOM; TREATMENT OUTCOME; CONGESTIVE HEART FAILURE; DIABETIC ANGIOPATHY; HEALTH BEHAVIOR; KIDNEY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE;

DIABETIC ANGIOPATHIES; HEALTH BEHAVIOR; HEART FAILURE, CONGESTIVE; KIDNEY; PATIENT COMPLIANCE; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038659231     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2001;104:2996-3007.
3. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002.
4. McKelvie RS, Benedict CR, Yusuf S. Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. Br Med J. 1999;318:1400-1402.
5. Mann JFE, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-636.
6. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
7. Abramson J, Berger A, Krumholz HM, Vaccarino, V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001;161:1725-1730.
8. McDonagh TA. Asymptomatic left ventricular dysfunction in the community. Curr Cardiol Rep. 2000;2:470-474.
9. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998;351:9-13.
10. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
11. Adams KF, Baughman KL, Dec WG, et al. HFSA guidelines for management of patients with heart failure caused by patients with left ventricular systolic dysfunction-pharmacologic approaches. I Card Fail. 1999;5:357-382.
12. Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol. 1999;33:916-923.
13. Vantrimpont P, Rouleau JL, Wun C et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. J Am Coll Cardiol. 1997;29:229-236.
14. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
15. Cooper HA, Exner DV, Domanski MJ. Light-to-moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:1753-1759.
16. Suskin N, Sheth R, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37:1677-1682.
17. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
18. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324:71-86.
19. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
20. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357:1385-1390.
21. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men-morbidity, risk factors and prognosis. J Intern Med. 2001;249:253-261.
22. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 91;121:951-957.
23. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;4:249-254.
24. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy with simvastatin in 20,536 high-risk individuals; a randomised placebo controlled trial. Lancet. 2002;360:7-22.
25. Bauersachs J, Galuppo P. Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001;104:982-985.
26. Dechend R, Fiebeler A, Park J, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation. 2001;104:576-581.
27. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol. 2001;87:819-822.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA. 2000;283:1967-1975.
29. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet. 2000;356:366-372.
30. Pahor M, Psaty BM, Aleterman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet. 2000;356:1949-1954.
31. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668-2673.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703-713.
33. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J. 1998;317:713-720.
34. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955-959.
35. UK Prospective Diabetes Study Group. Intensive blood-control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
36. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
37. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
38. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract. 1999;53:519-522.
39. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001;285:1971-1977.
40. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation. 2000;102:2700-2706.
41. Sakata Y, Masuyama T, Yamamoto K, et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation. 2000;102:2269-2275.
42. Creemers EEJM, Cleutjens JPM, Smits JFM, et al. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res. 2001;89:201-210.
43. Konertz W, Kleber FX, Dush S, et al. Initial efficacy trends with the acorn cardiac support device in patients with advanced heart failure. J Am Coll Cardiol. 2001;143A.
44. Mensche P, Vilquin JT, Desnos M, et al. Early results of autologous skeletal myoblast transplantation in patients with severe ischemic heart failure. Circulation. 2001;104:II598.
45. Lau CP, Yu CM, Chau E, et al. Reversal of left ventricular remodeling by synchronous biventricular pacing in heart failure. Pacing Clin Electrophysiol. 2000;23:1722-1725.